Christopher Salud
University of South Florida
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Christopher Salud.
Annals of Surgical Oncology | 2001
Richard J. Gray; Christopher Salud; Keoni Nguyen; Emilia L. Dauway; Jay L. Friedland; Claudia Berman; Eric S. Peltz; George F. Whitehead; Charles E. Cox
AbstractBackground: Standard wire localization (WL) and excision of nonpalpable breast lesions has several shortcomings. Methods: Ninety-seven women with nonpalpable breast lesions were prospectively randomized to radioactive seed localization (RSL) or WL. For RSL, a titanium seed containing 125I was placed at the site of the lesion by using radiographical guidance. The surgeon used a handheld gamma detector to locate and excise the seed and lesion. Results: Both techniques resulted in 100% retrieval of the lesions. Fewer RSL patients required resection of additional margins than WL patients (26% vs. 57%, respectively; P = .02). There were no significant differences in mean times for operative excision (5.4 vs. 6.1 minutes) or radiographical localization (13.9 vs. 13.2 minutes). There were also no significant differences in the subjective ease of the procedures as rated by surgeons, radiologists, and patients. All WLs were carried out on the same day as the excision, whereas RSL was performed up to 5 days before the operative procedure. Conclusions: RSL is as effective as WL for the excision of nonpalpable breast lesions and reduces the incidence of pathologically involved margins of excision. RSL also reduces scheduling conflicts and may allow elimination of intraoperative specimen mammography. RSL is an attractive alternative to WL.
Journal of The American College of Surgeons | 2001
Charles E. Cox; Christopher Salud; Alan Cantor; Siddarth S. Bass; Eric S. Peltz; Mark D. Ebert; Keoni Nguyen; Douglas S. Reintgen
BACKGROUND Implementation of new procedures, including lymphatic mapping for breast cancer, must be done and overseen by the medical community in a responsible way to ensure that the procedures are performed correctly. This study addresses the issues of adequacy of training and certification of surgeons performing lymphatic mapping. Ensuring quality in surgical care requires outcomes measures that are described in this study. STUDY DESIGN Sixteen surgeons performed lymphatic mapping in 2,255 patients with breast cancer using a combination blue dye and Tc99m-labeled sulfur colloid to identify the sentinel lymph nodes (SLNs). All participants were trained in a 2-day CME-accredited course. The Cox learning curve model (total number of mapping failures/total number of mapping cases) for a consecutive series of lymphatic mapping cases is described. The relationship of the Surgical Volume Index, the cases performed in a 30-day period, to the failure rate for each surgeon was modeled as a logistic regression curve (y = e(a+bx)/[1 + e(a+bx)]). RESULTS Surgeons performing less than three SLN biopsies per month had an average success rate of 86.23% +/- 8.30%. Surgeons performing three to six SLN biopsies per month had a success rate of 88.73% +/- 6.36%. Surgeons performing more than six SLN biopsies per month had a success rate of 97.81% +/- 0.44%. CONCLUSIONS This experience defines a learning curve for lymphatic mapping in breast cancer patients. Data suggest that increased volumes lead to decreased failure rates. These data provide surgeons performing SLN biopsy with a new paradigm for assessing their skill and adequacy of training and describes the relationship between volume of cases performed and success rate of SLN detection.
Breast Journal | 1999
Siddharth S. Bass; Gary H. Lyman; Christa R. McCann; Ni Ni Ku; Claudia Berman; Kara Durand; Monica Bolano; Sarah Cox; Christopher Salud; Douglas S. Reintgen; Charles E. Cox
▪ Abstract: The status of the regional nodal basin remains the most important prognostic indicator of survival. The current standard of care for the management of invasive breast cancer is the complete removal of the tumor, with documentation of negative margins by either mastectomy or lumpectomy, followed by complete axillary lymph node dissection. Data suggest that complete lymph node dissection (CLND) provides better local control of the disease and may actually offer a survival advantage. Lymphatic mapping and sentinel lymph node (SLN) biopsy are clearly changing this long‐held paradigm and have the potential to change the standard of surgical care of the breast cancer patient. The purpose of this report is to describe the lymphatic mapping experience at the H. Lee Moffitt Cancer Center and Research Institute. From April 1994 to January 1999, 1,147 consecutive breast cancer patients were enrolled in an institutional review board‐approved lymphatic mapping protocol. Lymphatic mapping was performed using Tc99m‐labeled sulfur colloid and isosulfan blue dye. An SLN was defined as any blue node and/or any hot node with ex vivo radioactivity counts 10 times an excised non‐SLN or in situ radioactivity counts 3 times the background counts. Lymphatic mapping was successful in identifying the SLN in 1,098 of 1,147 (95.7%) cases. In the first 186 patients, all of whom underwent CLND following SLN biopsy, one false‐negative biopsy was encountered for a false‐negative rate of 0.83%. The method of diagnosis (excisional versus minimally invasive) does not appear to impact on lymphatic mapping. Tumor size, however, is directly related to the probability of axillary lymph node involvement. Advances in technology and the development of minimally invasive surgical techniques have heralded a new era in surgery. Lymphatic mapping and SLN biopsy may actually prove to be a more accurate method of identifying metastases to the axilla by allowing a more focused pathologic examination of the axillary node(s) at highest risk for metastasis. With adequate training, this technique can be readily implemented as a valuable tool in the surgical treatment of breast cancer. ▪
Journal of The American College of Surgeons | 2001
Siddharth S. Bass; Charles E. Cox; Christopher Salud; Gary H. Lyman; Christa R. McCann; Elizabeth Dupont; Claudia Berman; Douglas S. Reintgen
BACKGROUND The technique of lymphatic mapping and sentinel lymph node (SLN) biopsy is rapidly becoming the preferred method of staging the axilla of the breast cancer patient. This report describes the impact of postinjection massage on the sensitivity of this surgical technique. STUDY DESIGN Lymphatic mapping at the H Lee Moffitt Cancer Center is performed using a combination of isosulfan blue dye and Tc99m labeled sulfur colloid. Data describing the rate of SLN identification and the node characteristics from 594 consecutive patients were calculated. Patients who received a 5-minute massage after injection of blue dye and radiocolloid were compared with a control group in which the patients did not receive a postinjection massage. RESULTS When compared with controls, the proportion of patients who had their SLN identified using blue dye after massage increased from 73.0% to 88.3%, and the proportion of patients who had their SLN identified using radiocolloid after massage increased from 81.7% to 91.3%. The overall rate of SLN identification increased from 93.5% to 97.8%. The proportion of nodes that were stained blue among those removed increased from 73.4% to 79.7% after massage. CONCLUSIONS As experience increases with this new procedure, the surgical technique of lymphatic mapping continues to evolve. The addition of a postinjection massage significantly improves the uptake of blue dye by SLNs and may also aid in the accumulation of radioactivity in the SLNs, further increasing the sensitivity of this procedure.
Surgical Clinics of North America | 2000
Charles E. Cox; Christopher Salud; Michael A. Harrinton
Axillary nodal status continues to be the most statistically significant predictor of survival for patients with breast cancer. Although still providing regional control of axillary disease, axillary dissection is more important as a staging and prognostic tool. Trials are currently underway to investigate the possibility of replacing the current standard treatment of breast cancer, axillary lymph node dissection, with the less invasive lymphatic mapping and sentinel lymph node biopsy. This issue and the technical aspects of sentinel lymph node mapping for breast cancer are discussed in detail in this article.
Annals of Surgical Oncology | 2001
Elisabeth L. Dupont; Charles E. Cox; Keoni Nguyen; Christopher Salud; Eric S. Peltz; George F. Whitehead; Mark D. Ebert; Ni Ni Ku; Douglas S. Reintgen
Background: Lymphatic mapping LM for breast cancer has made internal mammary node IMN detection practical and dependable. This study demonstrates the necessity of IMN removal when suggested by intraoperative radioguided surgery detection.Methods: From April 1998 to July 2000, 1273 patients underwent LM for breast cancer. LM was performed using the combined dye and radiocolloid technique. Patients were scanned operatively with a gamma probe over the IMN area, and most underwent preoperative lymphoscintigraphy. Nodes were removed from patients in whom radioactivity was detected in the internal mammary area.Results: Thirty of the 1273 2.4% patients mapped had at least one IMN removed. Twenty-two of 30 73.3% had inner quadrant lesions. Five of 30 16.7% patients had IMNs that were positive for metastatic disease. Three of these five had no metastatic spread to the axillary sentinel lymph node SLN. One of thirty 3.3% patients with IMN localization had neither hot nor blue nodes detected in an SLN procedure.Conclusions: Radioguided SLN detection should be attempted in the IMN basin with all tumors. If an IMN is identified, it should be removed. IMN biopsy is a feasible, low-risk procedure when directed by radioguided LM and provides a guide for radiotherapy for patients with positive IMNs.
Breast Cancer | 2000
Charles E. Cox; Christopher Salud; George F. Whitehead; Douglas S. Reintgen
Department of Surgery, H. Lee Moffitt Cancer Center and Research institute at the Universi~/of South Florida, Tampa, Florida, USA Reprint requests to Charles E. Cox, Department of Surgery, H Lee Moffitt Cancer Center and Research institute at the University of South Florida, 12902 Magnoha Drive, Tampa, FL 33612-9497, USA. Describe the advantages and disadvantages of Tc 99m Sulfur Colloid mapping for breast cancer.
American Surgeon | 2001
Charles E. Cox; Keoni Nguyen; Richard J. Gray; Christopher Salud; Ni Ni Ku; Elisabeth L. Dupont; Lorraine Hutson; Eric S. Peltz; George F. Whitehead; Douglas S. Reintgen; Alan Cantor
Annual Review of Medicine | 2000
Charles E. Cox; Siddharth S. Bass; Christa R. McCann; Ni Ni K. Ku; Claudia Berman; Kara Durand; Monica Bolano; Jessica Wang; Eric S. Peltz; Sarah Cox; Christopher Salud; Douglas S. Reintgen; Gary H. Lyman
Cancer Control | 1999
Charles E. Cox; Timothy J. Yeatman; Christopher Salud; Siddharth S. Bass